July 16, 2024—T-Neuro Pharma announced the publication of a landmark research article in Proceedings of the National Academy of Sciences (Panwar A, et al. Proc Natl Acad Sci USA. 2024;121(29):e2401420121). The article, “Antigen-Specific Age-Related Memory CD8 T Cells Induce and Track Alzheimer’s-like Neurodegeneration,” details a breakthrough in understanding the early events and progression of Alzheimer’s disease.
“This study is the closest we’ve come to identifying a singular factor acting before amyloid and tau—the proteins responsible for brain plaques and tangles—in sporadic Alzheimer’s disease,” Christopher Wheeler, PhD, lead author of the study and CSO of T-Neuro Pharma, said in a company press release. “Since this depends on a kind of immune cell that is easy to monitor and control, we can use this to devise new ways to help diagnose and possibly treat Alzheimer’s earlier. More work needs to be done to determine if the approaches inspired by our work can be applied to all patients with non-inherited forms of Alzheimer’s, but early evidence has been very encouraging.”
T-Neuro Pharma is an Albuquerque-based, clinical-stage biopharmaceutical company that develops diagnostics and disease-modifying therapies for Alzheimer’s and other neurodegenerative diseases.